XML 53 R43.htm IDEA: XBRL DOCUMENT v3.19.1
Revenue - Composition of Total Revenue by Product and U.S versus Rest of World (Detail) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Mar. 31, 2019
Mar. 31, 2018
Disaggregation Of Revenue [Line Items]        
Total revenue $ 216.6 $ 183.1 [1] $ 635.7 $ 549.8 [1]
U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 204.4 171.3 601.9 518.0
RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 12.2 11.8 33.8 31.8
Molecular Diagnostic - Hereditary Cancer Testing [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 117.6 113.1 360.7 352.2
Molecular Diagnostic - Hereditary Cancer Testing [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 114.3 110.4 351.4 344.5
Molecular Diagnostic - Hereditary Cancer Testing [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 3.3 2.7 9.3 7.7
Molecular Diagnostic - GeneSight [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 29.6 30.4 82.8 91.0
Molecular Diagnostic - GeneSight [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 29.6 30.4 82.8 91.0
Molecular Diagnostic - Prenatal [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 30.6   80.0  
Molecular Diagnostic - Prenatal [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 30.6   80.0  
Molecular Diagnostic- Vectra [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 11.3 15.0 36.1 40.1
Molecular Diagnostic- Vectra [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 11.3 15.0 36.1 40.1
Molecular Diagnostic - Prolaris [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 6.9 6.4 19.2 14.4
Molecular Diagnostic - Prolaris [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 6.9 6.3 19.1 14.3
Molecular Diagnostic - Prolaris [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue   0.1 0.1 0.1
Molecular Diagnostic - EndoPredict [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 2.8 2.3 7.4 6.1
Molecular Diagnostic - EndoPredict [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 0.5 0.2 1.2 0.3
Molecular Diagnostic - EndoPredict [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 2.3 2.1 6.2 5.8
Molecular Diagnostic - Other [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 1.7 2.1 6.3 5.9
Molecular Diagnostic - Other [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 1.5 2.0 5.8 5.5
Molecular Diagnostic - Other [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 0.2 0.1 0.5 0.4
Molecular Diagnostic Testing [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 200.5 169.3 [1] 592.5 509.7 [1]
Molecular Diagnostic Testing [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 194.7 164.3 576.4 495.7
Molecular Diagnostic Testing [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 5.8 5.0 16.1 14.0
Pharmaceutical and Clinical Services [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 16.1 13.8 [1] 43.2 40.1 [1]
Pharmaceutical and Clinical Services [Member] | U.S. [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue 9.7 7.0 25.5 22.3
Pharmaceutical and Clinical Services [Member] | RoW [Member]        
Disaggregation Of Revenue [Line Items]        
Total revenue $ 6.4 $ 6.8 $ 17.7 $ 17.8
[1] Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements contained in Part I, Item 1 of this report for additional information.